EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Arginase 1 is a key driver of immune suppression in pancreatic cancer

Rosa E Menjivar iD, Zeribe C Nwosu, Wenting Du, Katelyn L Donahue, Hanna S Hong, Carlos Espinoza, Kristee Brown, Ashley Velez-Delgado, Wei Yan, Fatima Lima, Allison Bischoff iD, Padma Kadiyala und 8 weitere

eLife · 2023

DOI: 10.7554/elife.80721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Rosa E Menjivar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States. Hauptthemen laut MEDLINE: Arginase, Pancreatic Neoplasms. Die Arbeit wurde bisher 176-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An extensive fibroinflammatory stroma rich in macrophages is a hallmark of pancreatic cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and contribute to the poor response to immunotherapy; however, the mechanisms of immune suppression are complex and not fully understood. Immunosuppressive macrophages are classically defined by the expression of the enzyme Arginase 1 (ARG1), which we demonstrated is potently expressed in pancreatic tumor-associated macrophages from both human patients and mouse models. While routinely used as a polarization marker, ARG1 also catabolizes arginine, an amino acid required for T cell activation and proliferation. To investigate this metabolic function, we used a genetic and a pharmacologic approach to target Arg1 in pancreatic cancer. Genetic inactivation of Arg1 in macrophages, using a dual recombinase genetically engineered mouse model of pancreatic cancer, delayed formation of invasive disease, while increasing CD8 + T cell infiltration. Additionally, Arg1 deletion induced compensatory mechanisms, including Arg1 overexpression in epithelial cells, namely Tuft cells, and Arg2 overexpression in a subset of macrophages. To overcome these compensatory mechanisms, we used a pharmacological approach to inhibit arginase. Treatment of established tumors with the arginase inhibitor CB-1158 exhibited further increased CD8 + T cell infiltration, beyond that seen with the macrophage-specific knockout, and sensitized the tumors to anti-PD1 immune checkpoint blockade. Our data demonstrate that Arg1 drives immune suppression in pancreatic cancer by depleting arginine and inhibiting T cell activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArginasePancreatic NeoplasmsAnimalsHumansMiceArginineCD8-Positive T-LymphocytesMacrophages

Stichwörter der Autor:innen

CD8 T cellsPDAarginasecancer biologyhumanimmunosuppressionimmunotherapymousemyeloid

Substanzen

ArginaseArginineArg1 protein, mouseARG1 protein, human

Autor:innen und Institutionen

  • Cellular and Molecular Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Cancer Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Department of Immunology, University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Department of Cell and Developmental Biology, University of Michigan-Ann Arbor, Ann Arbor, United States.

ORCID-Profile: Rosa E Menjivar, Allison Bischoff, Daniel Salas-Escabillas, Eileen Carpenter, Costas A Lyssiotis, Marina Pasca di Magliano

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • NICHD NIH HHS
  • NIDDK NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Menjivar, R. E., Nwosu, Z. C., Du, W., Donahue, K. L., Hong, H. S., Espinoza, C., Brown, K., Velez-Delgado, A., Yan, W., Lima, F., Bischoff, A., Kadiyala, P., Salas-Escabillas, D., Crawford, H. C., Bednar, F., Carpenter, E., Zhang, Y., Halbrook, C. J., Lyssiotis, C. A., & Pasca di Magliano, M. (2023). Arginase 1 is a key driver of immune suppression in pancreatic cancer. eLife. https://doi.org/10.7554/elife.80721

Vancouver

Menjivar RE, Nwosu ZC, Du W, Donahue KL, Hong HS, Espinoza C, et al. Arginase 1 is a key driver of immune suppression in pancreatic cancer. eLife. 2023. doi:10.7554/elife.80721

BibTeX
@article{Menjivar2023,
  author = {Menjivar, Rosa E and Nwosu, Zeribe C and Du, Wenting and Donahue, Katelyn L and Hong, Hanna S and Espinoza, Carlos and Brown, Kristee and Velez-Delgado, Ashley and Yan, Wei and Lima, Fatima and Bischoff, Allison and Kadiyala, Padma and Salas-Escabillas, Daniel and Crawford, Howard C and Bednar, Filip and Carpenter, Eileen and Zhang, Yaqing and Halbrook, Christopher J and Lyssiotis, Costas A and Pasca di Magliano, Marina},
  title = {Arginase 1 is a key driver of immune suppression in pancreatic cancer},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.80721}
}
Kostenlos starten →